Comparison of Efficiency and Safety Profile of Home-Based NB-UVB 311 Versus Outpatient NB-UVB 311 in the Treatment of Vitiligo



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Vitiligo is a chronic skin disorder where the loss of melanocytes results into repigmentation areas on the skin. Narrowband Ultraviolet B (NB-UVB) 311 nm phototherapy, characterized by its efficacy and safety, is widely accepted as an effective treatment of vitiligo with depigment repigmentation stabilization. This review compares the efficacy and safety of home-based NB-UVB therapy versus outpatient NB-UVB therapy. On the one hand, both procedures show comparable efficacies for producing significant repigmentation. In this sense, home-based therapy has the added advantages of convenience and flexibility while representing a real transformation from traditional model to modern pattern. But the success of home-based therapy depends highly on proper patient education and adherence to treatment protocols and regular monitoring to prevent misuse as well as potential adverse effects. Numbing of life Therapy provides the benefit of professional supervision, so that accurate dosing can be ensured and immediate intervention in case of any side effect can be given, thus making it more suitable for patients with complex medical conditions. The review also highlights the importance of telemedicine in enhancing the feasibility and safety of home-based therapy by allowing remote monitoring and as well as real-time support Telemedicine. Future research should focus on evaluating the cost-effectiveness of both modalities and ways to integrate advanced monitoring technologies into home care. Ultimately, the choice between home-based and out-patient NB-UVB therapy should be tailored to individual patient needs, thus ensuring the best possible treatment results.

About the authors

Mohammad Sulaiman Mohammad Al momani

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет), Россия

Email: Almomanimohamd65@gmail.com
ORCID iD: 0009-0009-9009-2239
Jordan

Konstantin M. Lomonosov

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: lamclinic@yandex.ru
ORCID iD: 0000-0002-4580-6193
SPIN-code: 4784-9730

D.Sc. (Med.), Professor

Russian Federation, Moscow

Syrine Smaoui

The First Sechenov Moscow State Medical University (Sechenov University)

Email: smaouicyrine1@gmail.com
ORCID iD: 0009-0006-1076-5674
Russian Federation, Moscow

Nadir ouaili

Email: ouaili.doctor@gmail.com
ORCID iD: 0009-0008-5715-8438

Ekaterina Melnik

Email: katerina.melnik.5@gmail.com
ORCID iD: 0000-0002-2500-7861
SPIN-code: 7418-1995

Faten Altameemi

Email: smart1995faten@gmail.com
ORCID iD: 0009-0000-8884-7713

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г
.